ENTO logo

Entero Therapeutics (ENTO) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

11 October 2016

Indexes:

Not included

Description:

Entero Therapeutics (ENTO) is a biotechnology company focused on developing innovative treatments for gastrointestinal diseases. They aim to improve patient outcomes by creating therapies that target the gut, helping to manage conditions like irritable bowel syndrome and other digestive disorders.

Events Calendar

Earnings

Next earnings date:

May 14, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 31, 2021
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Dec 18, 2023

Analyst ratings

Recent major analysts updates

15 Mar '24 Roth MKM
Buy
03 Jan '24 Roth MKM
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Entero Therapeutics, Inc. – ENTO
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Entero Therapeutics, Inc. – ENTO
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Entero Therapeutics, Inc. – ENTO
ENTO
globenewswire.com15 November 2024

NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Entero Therapeutics, Inc. (NASDAQ: ENTO ), relating to the proposed merger with Journey Therapeutics, Inc. Under the terms of the agreement, the shareholders of Journey will acquire 99% of the equity of Entero.

ENTO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Entero Therapeutics, Inc. Is Fair to Shareholders
ENTO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Entero Therapeutics, Inc. Is Fair to Shareholders
ENTO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Entero Therapeutics, Inc. Is Fair to Shareholders
ENTO
businesswire.com13 November 2024

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Entero Therapeutics, Inc. (NASDAQ: ENTO) and Journey Therapeutics, Inc. is fair to Entero shareholders. Upon closing of the proposed transaction, Journey shareholders will acquire 99% of the equity of Entero. Halper Sadeh encourages Entero shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh.

Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease
Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease
Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease
ENTO
globenewswire.com27 June 2024

New VCIEL scale provides a more sensitive and quantitative metric of small intestinal health for monitoring Celiac Disease severity and treatment efficacy

FAQ

  • What is the primary business of Entero Therapeutics?
  • What is the ticker symbol for Entero Therapeutics?
  • Does Entero Therapeutics pay dividends?
  • What sector is Entero Therapeutics in?
  • What industry is Entero Therapeutics in?
  • What country is Entero Therapeutics based in?
  • When did Entero Therapeutics go public?
  • Is Entero Therapeutics in the S&P 500?
  • Is Entero Therapeutics in the NASDAQ 100?
  • Is Entero Therapeutics in the Dow Jones?
  • When was Entero Therapeutics's last earnings report?
  • When does Entero Therapeutics report earnings?
  • Should I buy Entero Therapeutics stock now?

What is the primary business of Entero Therapeutics?

Entero Therapeutics (ENTO) is a biotechnology company focused on developing innovative treatments for gastrointestinal diseases. They aim to improve patient outcomes by creating therapies that target the gut, helping to manage conditions like irritable bowel syndrome and other digestive disorders.

What is the ticker symbol for Entero Therapeutics?

The ticker symbol for Entero Therapeutics is NASDAQ:ENTO

Does Entero Therapeutics pay dividends?

No, Entero Therapeutics does not pay dividends

What sector is Entero Therapeutics in?

Entero Therapeutics is in the Healthcare sector

What industry is Entero Therapeutics in?

Entero Therapeutics is in the Biotechnology industry

What country is Entero Therapeutics based in?

Entero Therapeutics is headquartered in United States

When did Entero Therapeutics go public?

Entero Therapeutics's initial public offering (IPO) was on 11 October 2016

Is Entero Therapeutics in the S&P 500?

No, Entero Therapeutics is not included in the S&P 500 index

Is Entero Therapeutics in the NASDAQ 100?

No, Entero Therapeutics is not included in the NASDAQ 100 index

Is Entero Therapeutics in the Dow Jones?

No, Entero Therapeutics is not included in the Dow Jones index

When was Entero Therapeutics's last earnings report?

Entero Therapeutics's most recent earnings report was on 13 November 2024

When does Entero Therapeutics report earnings?

The next expected earnings date for Entero Therapeutics is 14 May 2025

Should I buy Entero Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions